効果 | 増加 |
試験方法 | コホート法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 84 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
In women with PCOS, supplementation of 2,000mg _myo_-inositol was able to improve oocyte maturation and quality.
The Combined Therapy With Myo-inositol And D-chiro-inositol Reduces The Risk Of Metabolic Disease In PCOS Overweight Patients Compared To Myo-inositol Supplementation Alone
効果 | 増加 |
試験方法 | コホート法 |
試験期間 | 6+ ヶ月 |
被験者数 | 50 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
Supplementation of myo-inositol by itself at 2g daily for a period of six months in women with PCOS was associated with improvements in diastolic blood pressure. The combination with D-chiroinositol was the same at a lower dose (550mg and 13.8mg, respectively) when measured at six months, but seemed to act faster as inositol at 2g required six months to be fully effective.
Effects Of Inositol On Ovarian Function And Metabolic Factors In Women With PCOS: A Randomized Double Blind Placebo-controlled Trial
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 281 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
200mg of inositol daily (in two divided doses of 100mg) for a period of 12 weeks in women with PCOS was ineffective in improving the glucose metabolic markers yet was effective in reducing body weight and improving fertility.
Effects Of D-chiro-inositol In Lean Women With The Polycystic Ovary Syndrome
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 20 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 平均 |
6-8 weeks of supplementation with 600mg D-chiro-inositol daily in women with PCOS who also had an average BMI was able to increase ovulation secondary to reducing androgens, and appears to be effective in improving other biomarkers of health such as blood pressure and triglycerides.
Efficacy Of Myo-inositol In The Treatment Of Cutaneous Disorders In Young Women With Polycystic Ovary Syndrome
効果 | 増加 |
試験方法 | コホート法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 50 |
性別 | 女性 |
年齢 | 30-44 |
体型 | 平均 |
Supplementation of inositol in young women with PCOS (of which hirstuism and acne are common side effects) was therapeutic over the course of six months of treatment at 2,000mg.
Acne at baseline was either moderate (68%) or severe (32%) and, after supplementation, it was reduced respectively to 34% and 13% with more than half the sample (53%) noting an abolishment of all acne.
No placebo control group was used.
Metabolic And Hormonal Effects Of Myo-inositol In Women With Polycystic Ovary Syndrome: A Double-blind Trial
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 42 |
性別 | 男女 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
Supplementation of 4,000mg inositol daily for a period of 12-16 weeks in women with PCOS was able to improve tolerance to glucose and glucose handling (as well as reduce the amount of insulin secreted in response to a meal) with minor benefits to cardiovascular health as well.
Myo-inositol Administration Positively Affects Hyperinsulinemia And Hormonal Parameters In Overweight Patients With Polycystic Ovary Syndrome
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 20 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
2,000mg inositol daily in overweight women with PCOS
Inositol Administration Reduces Oxidative Stress In Erythrocytes Of Patients With Polycystic Ovary Syndrome
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 26 |
性別 | 女性 |
年齢 | 18-29 |
体型 | 平均 |
Supplementation of 1,200mg Myo-inositol daily for a period of 12 weeks in normal weight women (22-30yrs) with PCOS was able to decrease weight (−1.83+/-1.86kg, very unreliable in magnitude) and improved markers of glucose and androgen metabolism. An improvement in oxidative biomarkers was also noted (GSH in red blood cells).
Pretreatment With Myo-inositol In Non Polycystic Ovary Syndrome Patients Undergoing Multiple Follicular Stimulation For IVF: A Pilot Study
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 100 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満, 平均 |
A three month pretreatment of inositol supplementation in women with PCOS subject to undergo fertilization therapy noted that inositol at 2,000mg (400mcg folic acid also used as placebo) was more effective than placebo in improving fertilization rates and fertility.
Effects Of Myo-inositol Supplementation On Oocyte’s Quality In PCOS Patients: A Double Blind Trial
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 34 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
Three months supplementation of inositol at 2g daily in women with PCOS who then subsequently underwent ovarian induction noted that supplementation was associated with improved fertility.
Myo-inositol May Improve Oocyte Quality In Intracytoplasmic Sperm Injection Cycles. A Prospective, Controlled, Randomized Trial
効果 | 増加 |
試験方法 | 二重盲検法 |
試験期間 | 1-2 週間 |
被験者数 | 60 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
Supplementation of _myo_-inositol at 4g daily in women with PCOS undergoing ovulation induction for the purpose of intracytoplasmic sperm injections noted that supplementation resulted in improve oocyte maturation and reduced requirements of hormones needed to induce ovulation (rFSH). Pregnancy rates were not affected.
Myo-inositol In Patients With Polycystic Ovary Syndrome: A Novel Method For Ovulation Induction
効果 | 増加 |
試験方法 | コホート法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 25 |
性別 | 男女 |
年齢 | 30-44 |
体型 | 肥満, 平均 |
Supplementation of inositol at 2,000mg daily for an average of 35 days was associated with improved fertility and period regulatory over the course of the next six months.
Insulin Sensitiser Agents Alone And In Co-treatment With R-FSH For Ovulation Induction In PCOS Women
効果 | 増加 |
試験方法 | コホート法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 120 |
性別 | 男女 |
年齢 | 18-29, 30-44 |
体型 | 肥満 |
Supplementation of inositol at 4g daily (initially without FSH treatment, but it was introduced in both groups if no pregnancy occurred) was more effective than 1,500mg metformin in improving fertility rates in women with PCOS.
Randomized, Double Blind Placebo-controlled Trial: Effects Of Myo-inositol On Ovarian Function And Metabolic Factors In Women With PCOS
効果 | 減少 |
試験方法 | 二重盲検法 |
試験期間 | 1-6 ヶ月 |
被験者数 | 92 |
性別 | 女性 |
年齢 | 18-29, 30-44 |
体型 | 肥満, 肥満, 平均 |
4g of inositol daily for a period of 16 weeks in women with PCOS was ineffective in improving parameters of insulin sensitivity while it was sufficient to improve biomarkers of steroid metabolism and fertility. Weight was decreased in all subjects who were not morbidly obese.